



Amersham Place Little Chalfont, Buckinghamshire HP7 9NA

## Pre-notification of change in Legal Entity and company name

Dear valued customer.

As announced on February 25, 2019, Danaher Corporation intends to purchase the GE Healthcare Life Sciences business units consisting of BioProcess, Cell & Gene Therapy and Genomics & Cellular Research, (hereafter referred to as 'Biopharma'). The sale of the GE Healthcare Life Sciences Biopharma business to Danaher is subject to customary closing conditions, including regulatory reviews and appropriate consultation processes, and is expected to close as early as the first quarter of 2020.

We want this transition to be as smooth as possible for you. To allow us to continue serving you, we're notifying you now about upcoming changes that will require you to update your procurement systems.

## 1. The changes you should take note of:

The Biopharma United Kingdom Legal Entity (currently GE Healthcare UK Limited) will change on the effective date the transaction between GE and Danaher closes, as early as the first quarter of 2020. Please find below the details of the changes in Legal Entity. These Legal Entity changes will require you to update your procurement systems as soon as possible from the effective date. All open orders from the date of the Legal Entity change will be fulfilled in the New Legal Entity with shipping notifications and invoices from the New Legal Entity.

If you have already placed a purchase order under the Current Legal Entity, there is no need to reissue that purchase order, unless your company policy requires it.

We will provide further communication prior to the close date to confirm the effective date of these changes.

Below are our new supplier details – please prepare to update your systems with these once we confirm the effective date:

| Current Legal Entity                         | GE Healthcare UK Limited   |
|--|--|
| New Legal Entity                             | Global Life Sciences Solutions Operations UK Ltd                   |
| New Legal Entity Company Registration Number | 12063780   |
| New Legal Entity Registered Address          | 19 Jessops Riverside<br>800 Brightside Lane<br>Sheffield<br>S9 2RX |

|                               | United Kingdom<br>+44 1932 773820   |  |  |  |
|-------------------------------|---|--|--|--|
|                               | 144 1532 113020   |  |  |  |
| New Legal Entity VAT ID       | GB 333194219  |  |  |  |
|                               |   |  |  |  |
| New Legal Entity Bank Details | Account's Branch Name: HSBC Park Street                                       |  |  |  |
|                               | Bank Address: 62-76 Park Street, London Bridge, SE1 9DZ. SWIFT Code: MIDLGB22 |  |  |  |
|                               |   |  |  |  |
|                               | GBP: 404170-70002348 GB27MIDL40417070002348                                   |  |  |  |
|                               | EUR: 400515-84644789 GB33MIDL40051584644789                                   |  |  |  |
|                               | USD: 400515-84644797 GB11MIDL40051584644797                                   |  |  |  |
|                               |   |  |  |  |

Once the transaction closes, our company will become known as Cytiva, but the New Legal Entity name above will remain unchanged at this time.

We will share more details about the rebranding in due course and new product labelling will be done in phases. Finished products in our warehouses are rotated on a regular basis using first expired, first out inventory management. During the transition, documents for products and services will be changed gradually. This means that, for a period time, we require you to allow the receipt of goods from both the Current Legal Entity or New Legal Entity.

## 2. What will not change

Please be assured that we will continue to deliver our products and services to you as usual during this transition period. Our quality management system, processes for change control, change control notifications, manufacturing processes, locations and equipment will remain unchanged. There will be no change in our product part numbers or quality release claims. All terms of Legal agreements will remain in effect until agreement expiry or renewal. We look forward to continuing to deliver our products and services to you as usual during this transition period.

Please reach out to <u>ordersgb@ge.com</u> with any comments or feedback. We look forward to continuing to do business together.

For more information and regular updates visit our transition website: www.gelifesciences.com/4customers.

Yours sincerely,

James Savory

**EMEA Commercial Operations Leader** 

GE Healthcare Lifesciences

## **Appendix:**

<u>Legal Entity change for manufacturing sites:</u> Legal Entity information is often included in labeling and/or other product documentation such as Safety Data Sheets (SDS), Certificates, User documentation, etc. As needed, product documentation will be changed to include the updated Legal Entity information for the relevant manufacturing site of a product. Please note the finished products in our warehouses are rotated on a regular basis using first expired, first out inventory management and will not be re-labeled. It is important to note that, during the transition phase, document for products or services will be changed gradually.

| Region      | Current Legal Entity                   | New Legal Entity  | Sales Legal Entity<br>(Invoice) | Manufacturing<br>Legal Entity<br>(Product<br>documentation) | Impacts labels and product documentation (Y/N) | Effective from (date) Subject to change |
|-------------|--|---|---------------------------------|---|--|---|
| Sweden      | GE Healthcare Bio-Sciences<br>AB       | To be announced   | No                              | Yes   | Y  | After deal closure                      |
| USA         | HyClone Laboratories Inc               | HyClone Laboratories LLC                                  | No                              | Yes   | N  | Sept 30 2019                            |
| China       | GE Biotechnology (China)<br>Co. , Ltd. | To be announced   | No                              | Yes   | Y  | After deal closure                      |
| Germany     | Whatman GmbH                           | Global Life Sciences<br>Solutions Germany GmbH            | No                              | Yes   | N  | At deal closure                         |
| UK          | GE Healthcare Ltd                      | Global Life Sciences<br>Solutions Manufacturing UK<br>Ltd | No                              | Yes   | N  | At deal closure                         |
| UK          | Asymptote Ltd                          | No change   | No                              | Yes   | N  | Not applicable                          |
| Switzerland | Biosafe SA                             | No change   | No                              | Yes   | N  | Not applicable                          |